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Abstract
Purpose The aim of the present study was to evaluate the
quantitative and qualitative accuracy of 3D PET acquisi-
tions for myocardial FDG studies.
Methods Phantom studies were performed with both a
homogeneous and an inhomogeneous phantom. Activity
profiles were generated along the phantoms using 2D and
several 3D reconstructions, varying the 3D scaling value to
adjust the scatter correction algorithm. Furthermore, ten
patients underwent a dynamic myocardial FDG PET scan,
using an interleaved protocol consisting of frames with
alternating 2D and 3D acquisition. For each myocardial
study, 13 volumes of interest were defined, representing 13
myocardial segments. First, the optimal scaling value for
the scatter correction algorithm was determined using data
from the phantom and four patient studies. This scaling
value was then applied to all ten patients. 2D and 3D
acquisitions were compared for both static (i.e. activity
concentrations in the last 2D and 3D frames) and dynamic
imaging (calculation of the metabolic rate of glucose).
Results For both phantom and patient studies, suboptimal
results were obtained when the default scaling value for the
scatter correction algorithm was used. After adjusting the
scaling value, for all ten myocardial FDG studies, a very
good correlation (r2=0.99) was obtained between 2D and
3D data. With the present protocol no significant differ-
ences were observed in qualitative interpretation.
Conclusion The 3D FDG acquisition mode is accurate and
has clear advantages over the 2D mode for myocardial
FDG studies. A prerequisite is, however, optimisation of
the 3D scatter correction algorithm.
Keywords 3D . PET. 18F-FDG . Scatter . Myocardial
Introduction
Conventional positron emission tomography (PET) scan-
ners are equipped with interplane septa to limit the
detection of scattered (especially in the axial direction)
and random coincidences. A side-effect of these septa is
that only a small fraction of all true coincidences in the
axial field of view can be measured—in fact, only those
within the range of a few planes.
Modern PET scanners have retractable or no interplane
septa, thereby enabling a 3D scanning mode in which
coincidences can be measured throughout the axial field of
view. The system sensitivity of this 3D mode may be five to
six times higher than that of the 2D mode (∼3% instead of
∼0.5% of all decaying nuclei) [1].
18F-fluorodeoxyglucose (FDG) PET has been used
extensively to visualise and quantify myocardial glucose
metabolism [2–7], and it is an important tool for the
detection of myocardial viability. Performing clinical
studies in 3D rather than 2D acquisition mode may allow
for the use of less activity and/or shortening of the study
duration, without loss of image quality. The 3D scanning
mode, however, is accompanied by an increase in the
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scattered events of up to 50% of the total measured
coincidences [8, 9]. Therefore, dedicated scatter correction
methods are required [10]. Other problems affecting the
accuracy of 3D PET relate to attenuation correction,
detector normalisation and the increase in dead time and
randoms [11].
Most clinical experience with 3D PET has been obtained
with brain studies [12–14]. Data from cardiac studies are
limited and conflicting [15–19]. Due to differences in
scanner characteristics and imaging protocols, published
results cannot be used without further validation.
The aim of the present study was to determine the
accuracy of the 3D acquisition mode for both static and




All phantom and clinical studies were performed using an
ECAT EXACT HR+ scanner (CTI/Siemens, Knoxville,
TN). This scanner is equipped with BGO crystals and
acquires 63 planes of data over an axial field of view of
15 cm. Scans can be acquired in both 2D and 3D mode. For
attenuation correction, a transmission scan can be per-
formed using three rotating 68Ge line sources. The
characteristics of this scanner have been described in detail
elsewhere [20, 21]. In the present study, all acquisitions and
reconstructions were performed using ECAT software
version 7.2.
Reconstructions
All emission scans were reconstructed using filtered back
projection (FBP) with a Hanning filter at 5 mm full-width at
half-maximum. In the case of 3D emission scans, recon-
structions were performed using Fourier rebinning [22],
followed by 2D FBP using the same settings and filters. For
both 2D and 3D studies the resulting image resolution
equalled 6.8 mm at the centre of the field of view (FOV).
Normalisation, attenuation, scatter, dead time and decay
corrections were included in all reconstructions.
Scatter correction
For the purpose of the present study, the standard 3D scatter
algorithm provided by the manufacturer, which involves a
simulation-based method [23], was modified to allow
variation of the scaling (amplitude) of the scatter correction.
Although other parameters, such as energy window settings
or the number of simulations point, could also be varied,
the scaling (amplitude) of the scatter correction is a major
determinant of quantitatively accurate scatter correction, as
will be discussed in detail later. The default scaling is set to
2.3, which is an arbitrary value defined by the manufactur-
er. To evaluate the effects of the scaling of the scatter
correction on the accuracy of 3D scans, several 3D
emission scans were reconstructed with various scatter
scaling values (0, 1, 2.3, 3.5, 4, 4.5, 5 and 6) using both
phantom and clinical studies. Changing the scaling value of
the scatter correction algorithm affects the absolute values
of measured activity in the whole data set and therefore
requires an adjustment of the scanner calibration. The
optimal calibration factor was obtained from the phantom
studies. Subsequently, the optimal scaling value and
calibration factor were used for reconstruction of all clinical
3D emission scans. For reconstruction of 2D emission
scans, the default reconstruction software and (scatter)
corrections were used [20, 21]. The 2D scatter correction
involves a stationary convolution subtraction method [24].
Phantom studies
A number of phantom studies were performed to evaluate
the quantitative accuracy of 3D versus 2D acquisition
modes and to optimise calibration of the scanner and
(scaling of the) 3D scatter correction algorithm. The
following phantoms were used: (a) a homogeneous
20-cm-long, 20-cm-diameter phantom filled with an FDG
solution of ∼15 kBq/ml to evaluate the accuracy of the
calibration of the scanner; (b) the same phantom, but now
extended with an additional 20-cm-long phantom filled
with the same FDG solution to simulate outside FOV
activity; (c) the NEMA NU-2 1994 scatter phantom to
verify the accuracy of the scatter correction algorithm. The
latter phantom is a 20-cm-long, 20-cm-diameter phantom
with a 5-cm-diameter water-filled insert positioned 5 cm
from the axis of the phantom. The large background
compartment was filled with an FDG solution of
∼15 kBq/ml, while the insert contained no activity
(0 kBq/ml). For all these phantoms, both 15-min 2D and
15-min 3D emission scans were acquired. These scans
showed approximately 2.9E7 and 1.4E8 total numbers of
trues and random fractions of about 0.18 and 0.30 for 2D
and 3D scans, respectively. After activity had decayed to
background levels (after 12 h) a 15-min transmission was
performed for attenuation and scatter correction purposes.
Data were reconstructed as described above using various
scatter scaling values in the case of 3D reconstructions.
Analysis of phantom studies
The activity concentration in a 15-cm-diameter region of
interest (ROI), averaged over all image planes, in
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phantom (a) for both 2D and 3D scans was calculated
to verify the calibration of the scanner for 2D and 3D
scans. Furthermore, 2-cm-wide horizontal and vertical
profiles through the centre of the phantom were derived.
The effect of scaling the 3D scatter correction on the
level and variation of the reconstructed activity concen-
tration along the phantom x- and y-axis, was investigated.
Next, from phantom (b) the effect of outside FOV activity
on interplane variation of average activity concentration
was determined using a 15-cm-diameter ROI. Finally, to
determine the accuracy of the scatter correction algorithm,
a 2.5-cm ROI was placed within the cold insert of the
NEMA scatter phantom (phantom c) and several 5-cm
ROIs were placed in the warm background compartment.
The accuracy of the scatter correction algorithm was
evaluated using the cold spot recovery coefficient
(CSRC), defined here as the ratio between the measured
activity concentration in the 2.5-cm cold insert ROI and
the average activity concentration in the 5-cm background
ROIs. In theory, accurate scatter correction would result in
a CSRC equal to 0.0.
Clinical studies
Ten consecutive patients with ischaemic heart disease were
included. All patients had impaired left ventricular function
due to previous myocardial infarction, and were referred for
assessment of myocardial viability. All patients underwent
an FDG PET scan during a euglycaemic hyperinsulinaemic
clamp, a procedure that has been described elsewhere [25].
The study was approved by the Medical Ethics Com-
mittee of the VU University Medical Centre and informed
consent was obtained from each patient.
Clinical scanning protocol
After a short transmission scan for patient positioning, a
10-min transmission scan was performed to correct the
subsequent emission scan for attenuation. The emission
scan itself consisted of 35 frames with variable frame
length (6×5, 6×10, 3×20, 5×30, 5×60, 10×300 s) and a total
scan duration of 60 min. The start of this scan coincided
with the intravenous injection of ∼185 MBq of FDG.
During the first 10 min after injection, data acquisition was
performed in 3D mode. Thereafter alternating 2D and 3D
frames were acquired, each frame lasting 5 min.
The input function was obtained from continuous
arterial blood sampling [25]. At set times (5, 10, 20, 30
and 50 min after injection), continuous withdrawal was
interrupted for collection of manual samples. These
samples were measured in a well counter, cross-calibrated
against the PET scanner and used for on-line calibration of
the blood sampler and for determination of plasma to
whole blood 18F ratios. In addition, these samples were
used for measurement of plasma glucose levels (hexoki-
nase method, Hitachi 747, Boeringer Mannheim, Mann-
heim, Germany).
Analysis of clinical studies
In four patients the last 3D frame of the interleaved
dynamic scan was reconstructed as described above using
various scaling values of the 3D scatter correction algo-
rithm. All 2D frames of the interleaved dynamic scan were
reconstructed using the default settings of the reconstruc-
tion software as provided by the manufacturer. After
reconstruction, dynamic images were analysed using
standard Siemens/CTI reslicing and ROI software. Trans-
axial images of the left ventricle were reoriented according
to the anatomical axis of the heart and subsequently
displayed as short axis slices. The last 3D frame was used
for this reslicing procedure. Myocardial tissue ROIs were
manually defined on the short axis image and projected
onto both the 2D and the 3D data set. At the basal and
distal levels of the left ventricle, these ROIs divided each
short axis slice into six regions. At the apex, one ROI was
defined on each short axis slice. Additionally, ROIs were
defined at the basal level in the left ventricular cavity. For
each patient, corresponding ROIs from a variable number
of slices were grouped to compose 14 volumes of interest
(VOIs), representing 13 myocardial segments (six basal, six
distal and one apical) and one left ventricular cavity. Using
these VOIs, activity concentrations of the last 3D frame and
the average activity concentration of the last two 2D
frames, which preceded and followed the last 3D frame,
were determined. The ratio between 2D and 3D data was
calculated for all scaling values applied. The latter data
were used in conjunction with the phantom data to
determine optimal scaling of the 3D scatter correction
algorithm and to correct the calibration of the scanner, as
will be discussed later.
Next, all 3D frames of the interleaved dynamic scan
were reconstructed using these (optimal) settings for 3D
scatter correction and scanner calibration for all patients.
Activity concentrations of the last 3D frame and the
average activity concentration of the last two 2D frames
were now determined for all ten patients. The ratio between
2D and 3D data was plotted against the average 2D activity
concentration. Subsequently, the metabolic rate of glucose
(MRGlu) was calculated using Patlak graphical analysis
[26] over the period from 10 to 70 min post injection and
for 2D and 3D acquisitions separately.
Finally, the ratio of MRGlu obtained with 2D and 3D
PET was calculated.
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Statistical analysis
All data are expressed as mean values ±SD. Statistical
analyses were performed using the two-tailed paired t test
and least squares regression analysis. The limits of
agreement were assessed by means of the analysis
described by Bland and Altman [27]. A p value <0.05
was considered statistically significant.
Results
Phantom studies
Using profiles along a homogeneous phantom, the effect of
varying scatter correction scaling on reconstructed activity
concentration is demonstrated in Fig. 1a. The default
scaling (2.3) results in considerable overestimation. Apply-
ing scaling value 4.5 results in a more constant course and
it approaches the 2D profile. This effect is also seen in the
presence of activity outside the FOV (Fig 1b).
The CSRC linearly decreases with the use of higher
scaling values for scatter correction (Fig. 2). When higher
scaling values are used, the CSRC almost equals 0.
Clinical studies
Ten patients (seven male, three female) with a mean age
of 65±11 years were studied. The mean patient weight
was 84±17 kg and ranged from 70 to 126 kg. The mean
body mass index (BMI) was 28.6±6.5 kg/m2 and ranged
from 22.1 to 45.2 kg/m2.
Activity in the myocardial VOIs of the 2D studies was
on average 23.6±12.5 kBq/ml and ranged from 6.1 to
63.3 kBq/ml.
First, in line with the phantom studies, the effect of
varying the scatter correction scaling was evaluated in four
consecutive patients. Low scaling factors (e.g. the default
setting) resulted in overestimation of FDG concentration
(especially when activity was below 10 kBq/ml) using 3D
as compared with 2D acquisitions. A high scaling value
resulted in a considerable underestimation of FDG concen-
tration in regions with low activity. The optimal value for
both low and high activity levels (i.e. with the lowest SD)
appeared to be 4.5 (Fig. 3, Table 1). Mean activity was
overestimated by 10% using this scaling value (Table 1)
and this information was subsequently used to adjust the
3D calibration factor of the scanner.
The optimal scaling value was then applied to all ten
studies. A total of 130 segments were analysed. Activity in
the last 2D and 3D frames showed very good correlation
over a wide range of VOI values (y=1.01×−0.07, r2=0.99;
mean difference=0.24 kBq/ml, 2SD=2.40 kBq/ml) (Fig. 4).
Almost identical results were obtained when the analysis
was performed without the four patients who were used to
determine the optimal scaling value (y=1.04×−0.54;
r2=0.98; mean difference=0.41 kBq/ml, 2SD=2.78 kBq/ml,
n=6).
Mean MRGlu was 269±119 μmol/ml/min with 2D
acquisition and 274±128 μmol/ml/min with 3D acquisition
(p<0.001). 2D and 3D MRGlu values were closely correlated
(y=1.07×−0.01; r2=0.99; mean difference=5 μmol/ml/min,
2SD=31 μmol/ml/min) (Fig. 5). Performing the analysis
without the four patients who were used to determine the
optimal scaling value did not change the results (y=
1.09×−0.02; r2=0.98; mean difference=10 μmol/ml/min,
2SD=34 μmol/ml/min, n=6).
Fig. 1 a 2D profile of normalised activity concentration (ratio
between reconstructed phantom activity concentration and that
obtained from samples in a well counter) along a homogeneous
phantom with corresponding 3D profiles with varying scaling values
(Sc) applied to the scatter correction. b Effect of outside FOV activity
on measured activity concentration per plane using 2D reconstruction
and 3D with two different scaling values applied to the scatter
correction
1442 Eur J Nucl Med Mol Imaging (2007) 34:1439–1446
Qualitative analysis
With one exception, all images were of good quality with
only small differences between 2D and 3D images, the
latter being slightly smoother in general appearance
(Fig. 6). As no difference in image resolution was observed,
this is the result of differences in counting statistics. 2D and
3D images of one study were of inferior quality, probably
owing to insulin resistance and adiposity of the patient.
Discussion
The purpose of the present study was to evaluate the
quantitative and qualitative accuracy of 3D FDG PET in
cardiac studies. As 3D acquisitions may introduce bias due
to a significant increase in scattered events as compared
with 2D, accuracy of the scatter correction algorithm plays
a prominent role in 3D image reconstruction.
Using phantom studies it was demonstrated that the
scatter correction algorithm was suboptimal when the
default settings (scaling value of 2.3) of the manufacturer
were used. Adjusting the scaling value resulted in 3D data
that more closely resembled data from 2D acquisitions. A
scaling value of 4.5 was considered to be optimal as the
absolute difference in measured activity with 2D was
minimal. Moreover, the activity profile along the phantom
showed fewer fluctuations, making it easier to determine
the 3D calibration factor. These effects were also seen in the
presence of activity outside the FOV, a situation that is
normal for clinical myocardial FDG PET studies because of
high FDG uptake in the liver. Furthermore, only with high
Fig. 2 Linear plot through the cold spot recovery coefficient (CSRC)
for different 3D scatter scaling values. The CSRC for 2D acquisition
was 0.025±0.05 (1SD)
Fig. 3 Ratio of 3D and 2D FDG concentration using different scaling
values (Sc) for scatter correction in 3D reconstructions, as a function
of the 2D ROI value
Table 1 Mean ratio and SD of activity between 3D and 2D
reconstructions using different scaling values for 3D scatter correction
Sc 2.3 Sc 3.5 Sc 4.5 Sc 5.5
Mean 1.45 1.18 1.10 0.95
SD 0.46 0.17 0.11 0.19
Fig. 4 a Scatterplot of the correlation between activity in the last 3D
frame and the mean activity in the last two 2D frames. b Limits of
agreement between 2D and 3D ROI values. Horizontal lines represent
the mean difference and mean±2SD
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scaling values could a low CSRC be obtained for the scatter
phantom.
To further explore these findings in a clinical setting,
four consecutive myocardial FDG studies were used to
reconstruct the same (static) images with varying scatter
scaling values. In accordance with the results of the
phantom studies, for the default scatter scaling factor,
FDG concentration was overestimated compared with 2D
data, especially in areas with low FDG concentrations
(<10 kBq/ml). In contrast, high scaling values resulted in
severe underestimation in areas with low FDG concen-
trations (Fig. 3).
The best results, over a wide range of FDG concentrations,
were obtained with a scaling value of 4.5. This was also
reflected in the lowest SD of all scaling values tested
(Table 1). As 4.5 was considered to be the optimal scaling
value, it was applied to all ten myocardial FDG PET studies.
Using this scatter scaling value, FDG concentrations of
static 3D and 2D frames showed a good correlation. One
study was of inferior quality in both 2D and 3D acquisition
[probably due to obesity (BMI 45.2 kg/m2) and insulin
resistance of the patient] and resulted in underestimation of
FDG concentrations with 3D acquisition. Increased scatter
in this heavy patient may have contributed to the differ-
ences between 2D and 3D results. The impaired image
quality with increasing patient weight in 3D PET scanning
has already been addressed [28–30]. However, no data were
discarded with respect to the statistical analyses.
The same favourable results were obtained when a
comparison was made between MRGlu values calculated
for 2D and 3D data separately, although a small overesti-
mation at high activity levels was observed with 3D
acquisition. Probably this is still due to a suboptimal scatter
scaling value and 3D calibration factor. A different
behaviour of the 3D scatter correction algorithm with
changing activity distribution during the dynamic scan
could also contribute to this finding as this pattern was not
observed when the activity levels of the last 2D and 3D
frames of the dynamic scan were compared. It is likely that
the small differences between the 2D and 3D data will have
no clinical significance.
The good correlation of 2D and 3D data is in line
with earlier reports comparing 2D and 3D FDG PET [18,
19, 29]. However, in a recent study inaccuracy of 3D
imaging was demonstrated especially in regions with low
FDG uptake, probably reflecting a suboptimal scatter
correction [19].
In the present study, comparing a 10-min 2D emission
image with a 5-min 3D emission image, no significant
differences were observed in image quality and qualitative
interpretation. This supports the use of 3D acquisition in
clinical practice.
Limitations
The four patients from whom the optimal scaling value was
derived were part of the final study population and this
could be a confounding factor. However, excluding the four
Fig. 5 a Scatterplot of the correlation between 2D and 3D MRGlu.
b Limits of agreement between 2D and 3D MRGlu. Horizontal lines
represent the mean difference and mean±2SD
Fig. 6 Representative examples of transaxial 2D and 3D images
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patients from the analysis did not significantly affect the
results.
This procedure contains both phantom and clinical
studies. Clearly, more phantom studies could have been
included. The clinical results indicate, however, that use of
the phantoms and experiments as described in the NEMA
NU2 1994 protocols is sufficient.
The present results are only applicable to the HR+
scanner with its specific reconstruction software (version
7.2.1) using a procedure aimed at optimising the accuracy
of 3D acquisitions and reconstructions. It should be noted
that a similar evaluation is required for every scanner with
its own specific reconstruction software before the accuracy
of 3D acquisitions can be guaranteed. This is also true for
PET/CT scanners, even if the PET geometry is the same as
that of a conventional PET scanner. A larger gantry and
possibly less internal side-shielding of detectors (due to the
presence of the CT) may affect the results.
The present results were obtained with a PET scanner
equipped with bismuth germanate (BGO) scintillation
crystals. At present both lutetium oxyorthosilicate (LSO)-
based PET and PET/CT scanners are commercially avail-
able. As the scintillation decay time of LSO crystals is
shorter and thus a smaller coincidence time window can be
applied, randoms and dead time will be reduced and scatter
rejection may be improved by a narrower energy window.
Therefore, we expect that it should be possible to achieve at
least comparable results as compared with BGO-based PET
scanners [31]. However, accuracy of the 3D acquisition
mode will be influenced by the same factors as are
described in the present study. Furthermore, a substantial
number of PET/CT scanners are still equipped with BGO
crystals [32].
A dose of ∼185 MBq FDG was injected to perform the
clinical studies. As a consequence, results obtained in this
study cannot be extrapolated to high count rate studies (e.g.
in the case of 82Rb and 15O studies) as these result in a
significant increase in dead time and randoms. Due to these
effects, high count rate studies should not be performed
using 3D acquisitions with a BGO-based scanner [17].
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